Lantheus Holdings, a provider of medical imaging technologies, recently reported strong Q1 earnings that beat expectations and raised guidance. The company specializes in prostate cancer detection and imaging. Despite a sell-off in the stock due to competition in the field, analysts believe Lantheus will maintain its lead position and see significant growth. The stock has been given a price target of $125 per share, presenting an attractive risk/reward opportunity for investors.
Thu, 06 Jul 2023 09:20:00 GMT | Yahoo Finance